Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor
Background: In many cancer cells, L-type amino acid transporter 1 (LAT1) transports neutral amino acids with bulky side chain, which activate mammalian target of rapamycin (mTOR) to cause cell proliferation. An anti-diabetic drug, metformin, has been shown to activate AMP-activated protein kinase (A...
Main Authors: | Seiji Ueno, Toru Kimura, Takashi Yamaga, Akihiko Kawada, Toshiaki Ochiai, Hitoshi Endou, Hiroyuki Sakurai |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-06-01
|
Series: | Journal of Pharmacological Sciences |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S134786131630038X |
Similar Items
-
Metformin inhibits the development and metastasis of colorectal cancer
by: Hasegawa, H., et al.
Published: (2022) -
Metformin as an energy restriction mimetic agent for breast cancer prevention
by: Zongjian Zhu, et al.
Published: (2011-01-01) -
Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells
by: Keyan Cheng, et al.
Published: (2016-11-01) -
Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways
by: Kengo Shimazu, et al.
Published: (2017-05-01) -
Metformin induces degradation of mTOR protein in breast cancer cells
by: Mohamed Alalem, et al.
Published: (2016-11-01)